Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Workshops With Experts: Advances to Improve Clinical Outcomes for Veterans With Pancreatic Cancer
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: April 15, 2021 Expiration: April 14, 2022
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Ipsen Biopharmaceuticals, Inc.
Andrew H. Ko, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Consider efficacy and safety evidence as well as patient characteristics and preferences to individualize therapeutic strategies for patients with newly diagnosed pancreatic cancer and advanced pancreatic cancer following first-line systemic therapy based on available data and treatment guidelines (maintenance or progression)
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations 
  • Appraise the rationale for available/emerging data for the use of novel chemotherapy platforms, PARP inhibitors, immunotherapy (and immunotherapy-based combinations), stroma-targeting agents, and tumor treating fields therapy (TTFields), and others for pancreatic cancer
  • Manage disease-related and treatment-related symptoms for patients with advanced pancreatic cancer
  • Identify patients suitable for enrollment on ongoing clinical studies of emerging investigational agents and treatment strategies in advanced pancreatic cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Andrew H. Ko, MD

Professor
Division of Hematology/Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Andrew H. Ko, MD, has disclosed that he has received funds for research support paid to his institution from AbGenomics, Apexigen, Astellas, Bristol-Myers Squibb, Celgene, Merck, and Roche/Genentech and has received consulting fees from Erytech, Imugene, Ipsen, Roche/Genentech, and SynCore.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals working within the VHA system who care for patients with pancreatic cancer.

Goal

The goal of this activity is to improve the competence and performance of learners to select and apply and optimal therapeutic strategies for veterans with newly diagnosed or relapsed/refractory pancreatic ductal adenocarcinoma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-080-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 15, 2021, through April 14, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Workshops With Experts: Advances to Improve Clinical Outcomes for Veterans With Pancreatic Cancer
  • CME
  • CE

Loading...
In this interactive on-demand webcast, expert faculty discuss best practices and emerging strategies in the treatment of patients with newly diagnosed or progressive advanced pancreatic cancer.
Andrew H. Ko, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: April 15, 2021 Expiration: April 14, 2022

Related Content

Download slides from Clinical Care Options (CCO) in which experts provide multidisciplinary insights on the use of checkpoint inhibitors for HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: April 30, 2021

In this slideset from Clinical Care Options (CCO), experts discuss their thoughts on the use of regorafenib and TAS-102 for colorectal cancer (CRC).

person default Joleen Hubbard, MD John L. Marshall, MD Released: April 29, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021

Laurie Cohen, MD, on when and how to retest for GH deficiency, how soon to start GH replacement in cancer survivors from Clinical Care Options (CCO)

Laurie E. Cohen, MD Released: April 22, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Ipsen Biopharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue